{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:01:37Z","timestamp":1789956097358,"version":"4.0.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":82,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-026-06206-9","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:46:25Z","timestamp":1782920785000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of routine inflammatory biomarkers and derived indices with heart failure progression in preserved ejection fraction"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4085-8151","authenticated-orcid":false,"given":"\u00c7a\u011fr\u0131","family":"Zorlu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6209-1732","authenticated-orcid":false,"given":"Sefa Erdi","family":"\u00d6m\u00fcr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6187-9973","authenticated-orcid":false,"given":"Volkan","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7532-3838","authenticated-orcid":false,"given":"G\u00f6khan","family":"G\u00fcng\u00f6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"6206_CR1","doi-asserted-by":"crossref","unstructured":"Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272-87.\u00a0(Erratum in: Cardiovasc Res. 2023;119(6):1453).","DOI":"10.1093\/cvr\/cvac013"},{"key":"6206_CR2","doi-asserted-by":"publisher","first-page":"638","DOI":"10.3389\/fphys.2019.00638","volume":"10","author":"AB Gevaert","year":"2019","unstructured":"Gevaert AB, Boen JRA, Segers VF, Van Craenenbroeck EM. Heart failure with preserved ejection fraction: a review of cardiac and noncardiac pathophysiology. Front Physiol. 2019;10:638.","journal-title":"Front Physiol"},{"issue":"10","key":"6206_CR3","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jacc.2018.06.050","volume":"72","author":"J Tromp","year":"2018","unstructured":"Tromp J, Westenbrink BD, Ouwerkerk W, et al. Identifying pathophysiological mechanisms in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol. 2018;72(10):1081\u201390.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"6206_CR4","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1007\/s11010-024-05122-w","volume":"480","author":"S Ghiasi Hafezi","year":"2025","unstructured":"Ghiasi Hafezi S, Kolahi Ahari R, Saberi-Karimian M, et al. Association of high-sensitivity C-reactive protein and hematologic-inflammatory indices with risk of cardiovascular diseases: a population-based study with partial least squares structural equation modeling approach. Mol Cell Biochem. 2025;480(3):1909\u201318.","journal-title":"Mol Cell Biochem"},{"issue":"6","key":"6206_CR5","first-page":"606","volume":"105","author":"E Durmus","year":"2015","unstructured":"Durmus E, Kivrak T, Gerin F, Sunbul M, Sari I, Erdogan O. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are predictors of heart failure. Arq Bras Cardiol. 2015;105(6):606\u201313.","journal-title":"Arq Bras Cardiol"},{"issue":"1","key":"6206_CR6","doi-asserted-by":"publisher","first-page":"e026326","DOI":"10.1161\/JAHA.122.026326","volume":"12","author":"S Tamaki","year":"2023","unstructured":"Tamaki S, Nagai Y, Shutta R, et al. Combination of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as a novel predictor of cardiac death in patients with acute decompensated heart failure with preserved left ventricular ejection fraction: a multicenter study. J Am Heart Assoc. 2023;12(1):e026326.","journal-title":"J Am Heart Assoc"},{"issue":"18","key":"6206_CR7","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.3390\/diagnostics14182102","volume":"14","author":"L Cristescu","year":"2024","unstructured":"Cristescu L, Tilea I, Iancu DG, et al. Insights into the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio as predictors for the length of stay and readmission in chronic heart failure patients. Diagnostics (Basel). 2024;14(18):2102.","journal-title":"Diagnostics (Basel)"},{"issue":"10","key":"6206_CR8","first-page":"1473","volume":"58","author":"R Wang","year":"2022","unstructured":"Wang R, Wu J, Ye H, Zhang X, Wang L. Application value of systemic inflammatory indexes in the clinical evaluation of patients with heart failure with preserved ejection fraction (HFpEF). Med (Kaunas). 2022;58(10):1473.","journal-title":"Med (Kaunas)"},{"issue":"6","key":"6206_CR9","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/00365513.2023.2233890","volume":"83","author":"D Inan","year":"2023","unstructured":"Inan D, Erdogan A, Pay L, et al. The prognostic impact of inflammation in patients with decompensated acute heart failure, as assessed using the pan-immune inflammation value (PIV). Scand J Clin Lab Invest. 2023;83(6):371\u20138.","journal-title":"Scand J Clin Lab Invest"},{"issue":"1","key":"6206_CR10","doi-asserted-by":"publisher","first-page":"20072","DOI":"10.1038\/s41598-022-24226-1","volume":"12","author":"JA Regan","year":"2022","unstructured":"Regan JA, Truby LK, Tahir UA, et al. Protein biomarkers of cardiac remodeling and inflammation associated with HFpEF and incident events. Sci Rep. 2022;12(1):20072.","journal-title":"Sci Rep"},{"issue":"36","key":"6206_CR11","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021;42(36):3599\u2013726. Corrigendum in: Eur Heart J. 2021;42(48):4901.","journal-title":"Eur Heart J"},{"issue":"9","key":"6206_CR12","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.3390\/jcm14092957","volume":"14","author":"M Yildirim","year":"2025","unstructured":"Yildirim M, Salbach C, Mueller-Hennessen M, et al. Diagnostic and prognostic evaluation of novel biomarkers compared to ESC 0\/1 h and 0\/3 h algorithms in patients with suspected non-ST-elevation myocardial infarction. J Clin Med. 2025;14(9):2957.","journal-title":"J Clin Med"},{"issue":"7","key":"6206_CR13","doi-asserted-by":"publisher","first-page":"465","DOI":"10.31128\/AJGP-03-19-4873","volume":"48","author":"P Naing","year":"2019","unstructured":"Naing P, Forrester D, Kangaharan N, Muthumala A, Mon Myint S, Playford D. Heart failure with preserved ejection fraction: a growing global epidemic. Aust J Gen Pract. 2019;48(7):465\u201371.","journal-title":"Aust J Gen Pract"},{"issue":"18","key":"6206_CR14","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1093\/cvr\/cvac133","volume":"118","author":"NR Pugliese","year":"2023","unstructured":"Pugliese NR, Pellicori P, Filidei F, et al. Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions. Cardiovasc Res. 2023;118(18):3536\u201355.","journal-title":"Cardiovasc Res"},{"issue":"Suppl 1","key":"6206_CR15","doi-asserted-by":"publisher","first-page":"ehae6661203","DOI":"10.1093\/eurheartj\/ehae666.1203","volume":"45","author":"Y Kokubu","year":"2024","unstructured":"Kokubu Y, Watanabe T, Yamada T, et al. Prognostic impact of systemic immune-inflammation index in patients with acute decompensated heart failure with preserved ejection fraction - PURSUIT-HFpEF Registry. Eur Heart J. 2024;45(Suppl 1):ehae6661203.","journal-title":"Eur Heart J"},{"issue":"5","key":"6206_CR16","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3390\/jcm13051295","volume":"13","author":"Z Cetinkaya","year":"2024","unstructured":"Cetinkaya Z, Kelesoglu S, Tuncay A, et al. The role of pan-immune-inflammation value in determining the severity of coronary artery disease in NSTEMI patients. J Clin Med. 2024;13(5):1295.","journal-title":"J Clin Med"},{"key":"6206_CR17","doi-asserted-by":"publisher","first-page":"131818","DOI":"10.1016\/j.ijcard.2024.131818","volume":"402","author":"JP Ferreira","year":"2024","unstructured":"Ferreira JP, Claggett BL, Liu J, et al. High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: findings from TOPCAT. Int J Cardiol. 2024;402:131818.","journal-title":"Int J Cardiol"},{"issue":"1","key":"6206_CR18","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1186\/s12872-023-03572-6","volume":"23","author":"M Vakhshoori","year":"2023","unstructured":"Vakhshoori M, Nemati S, Sabouhi S, et al. Neutrophil to lymphocyte ratio (NLR) prognostic effects on heart failure: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2023;23(1):555.","journal-title":"BMC Cardiovasc Disord"},{"key":"6206_CR19","doi-asserted-by":"publisher","first-page":"31370","DOI":"10.1038\/s41598-024-82826-5","volume":"14","author":"H Wang","year":"2024","unstructured":"Wang H, Huang Z, Wang J, et al. Predictive value of system immune-inflammation index for the severity of coronary stenosis in patients with coronary heart disease and diabetes mellitus. Sci Rep. 2024;14:31370.","journal-title":"Sci Rep"},{"issue":"23","key":"6206_CR20","doi-asserted-by":"publisher","first-page":"e036970","DOI":"10.1161\/JAHA.124.036970","volume":"13","author":"J Wang","year":"2024","unstructured":"Wang J, Wang Y, Duan S, et al. Multimodal data-driven prognostic model for predicting long-term prognosis in patients with ischemic cardiomyopathy and heart failure with preserved ejection fraction after coronary artery bypass grafting: a multicenter cohort study. J Am Heart Assoc. 2024;13(23):e036970.","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"6206_CR21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s12012-024-09855-4","volume":"24","author":"M Kaplangoray","year":"2024","unstructured":"Kaplangoray M, Toprak K, Deveci E, Caglayan C, \u015eahin E. Could pan-immune-inflammation value be a marker for the diagnosis of coronary slow flow phenomenon? Cardiovasc Toxicol. 2024;24(5):519\u201326.","journal-title":"Cardiovasc Toxicol"},{"issue":"2","key":"6206_CR22","doi-asserted-by":"publisher","first-page":"e011146","DOI":"10.1161\/CIRCHEARTFAILURE.123.011146","volume":"17","author":"JD Azzo","year":"2024","unstructured":"Azzo JD, Dib MJ, Zagkos L, et al. Proteomic associations of NT-proBNP (N-terminal pro-B-type natriuretic peptide) in heart failure with preserved ejection fraction. Circ Heart Fail. 2024;17(2):e011146.","journal-title":"Circ Heart Fail"},{"key":"6206_CR23","doi-asserted-by":"crossref","unstructured":"Biancucci M et al. Hypoalbuminaemia and heart failure: A practical review of pathophysiology and clinical implications. Eur J Heart Fail. 2025;27(2):293\u2013306.","DOI":"10.1002\/ejhf.3363"},{"key":"6206_CR24","doi-asserted-by":"publisher","first-page":"1461073","DOI":"10.3389\/fcvm.2024.1461073","volume":"11","author":"Z Fu","year":"2024","unstructured":"Fu Z, Liu P, Gao X, et al. Association of systemic inflammatory markers with clinical adverse prognosis and outcomes in HFpEF: a systematic review and meta-analysis of cohort studies. Front Cardiovasc Med. 2024;11:1461073.","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"6206_CR25","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1002\/ehf2.13187","volume":"8","author":"Y Sun","year":"2021","unstructured":"Sun Y, Wang N, Li X, et al. Predictive value of H2 FPEF score in patients with heart failure with preserved ejection fraction. ESC Heart Fail. 2021;8(2):1244\u201352.","journal-title":"ESC Heart Fail"},{"issue":"10","key":"6206_CR26","doi-asserted-by":"publisher","first-page":"e039379","DOI":"10.1161\/JAHA.124.039379","volume":"14","author":"M Yildirim","year":"2025","unstructured":"Yildirim M, Salbach C, Mueller-Hennessen M, et al. Comparative analysis of single- and dual-marker strategies for rapid non-ST-segment-elevation myocardial infarction rule-out using cardiac myosin-binding protein C, copeptin, and high-sensitivity cardiac troponin T in the emergency department. J Am Heart Assoc. 2025;14(10):e039379.","journal-title":"J Am Heart Assoc"},{"key":"6206_CR27","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12872-022-02656-z","volume":"22","author":"NW Carris","year":"2022","unstructured":"27, Carris NW, Mhaskar R, Coughlin E, et al. Novel biomarkers of inflammation in heart failure with preserved ejection fraction: analysis from a large prospective cohort study. BMC Cardiovasc Disord. 2022;22:221.","journal-title":"BMC Cardiovasc Disord"},{"issue":"6","key":"6206_CR28","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/eurheartj\/ehaa943","volume":"42","author":"WT Abraham","year":"2021","unstructured":"Abraham WT, Lindenfeld J, Ponikowski P, et al. Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. Eur Heart J. 2021;42(6):700\u201310.","journal-title":"Eur Heart J"},{"key":"6206_CR29","doi-asserted-by":"publisher","first-page":"875327","DOI":"10.3389\/fcvm.2022.875327","volume":"9","author":"H Zhou","year":"2022","unstructured":"Zhou H, Peng W, Li F, et al. Effect of sodium-glucose cotransporter 2 inhibitors for heart failure with preserved ejection fraction: a systematic review and meta-analysis of randomized clinical trials. Front Cardiovasc Med. 2022;9:875327.","journal-title":"Front Cardiovasc Med"},{"issue":"10289","key":"6206_CR30","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","volume":"397","author":"PM Ridker","year":"2021","unstructured":"Ridker PM, Devalaraja M, Baeres FMM, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397(10289):2060\u20139.","journal-title":"Lancet"},{"issue":"37","key":"6206_CR31","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1093\/eurheartj\/ehad389","volume":"44","author":"AK Pandey","year":"2023","unstructured":"Pandey AK, Bhatt DL, Pandey A, et al. Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction. Eur Heart J. 2023;44(37):3640\u201351.","journal-title":"Eur Heart J"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-06206-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06206-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06206-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T01:48:43Z","timestamp":1789955323000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-06206-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6206"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-06206-9","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"9 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the local Ethics Committee (Protocol No: 25-MOBAEK-181). Due to the retrospective design, individual informed consent was not required; patient data were analyzed anonymized.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"819"}}